Nurix Therapeutics
NRIX
182 hedge funds and large institutions have $2.15B invested in Nurix Therapeutics in 2025 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 93 increasing their positions, 29 reducing their positions, and 28 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
221% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 29
192% more call options, than puts
Call options by funds: $4.74M | Put options by funds: $1.63M
175% more capital invested
Capital invested by funds: $783M → $2.15B (+$1.37B)
39% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 28
36.63% more ownership
Funds ownership: 110.89% → 147.52% (+37%)
5% more funds holding
Funds holding: 173 → 182 (+9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GA
General Atlantic
New York
|
+$70.4M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$63.4M |
| 3 |
Morgan Stanley
New York
|
+$37.6M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$35.5M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
+$31.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$66.8M |
| 2 |
CC
Commodore Capital
New York
|
-$21.6M |
| 3 |
Millennium Management
New York
|
-$19.3M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$17.3M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$14.7M |
NRIX Hedge Fund Activity: Q4 2025 in Review
182 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q4 2025, worth a combined $2.15B — up 175% from $783M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new NRIX positions and 28 closed out — a net gain of 11 holders — while 93 added to existing stakes and 29 trimmed.
The largest buyer was General Atlantic, opening a new position worth an estimated $70.4M. The largest seller was Fidelity Investments, cutting an estimated $66.8M.
- 182 institutional investors held Nurix Therapeutics (NRIX) as of Q4 2025, up from 173 in Q3 2025.
- Funds reported $2.15B of Nurix Therapeutics stock for Q4 2025, up 175% quarter-over-quarter.
- 39 funds opened new Nurix Therapeutics positions in Q4 2025 and 28 closed out, a net change of +11 holders.
- The largest Nurix Therapeutics buyer in Q4 2025 was General Atlantic, an estimated $70.4M added.
- The largest Nurix Therapeutics seller in Q4 2025 was Fidelity Investments, an estimated $66.8M sold.
Based on aggregated 13F filings for Q4 2025.